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Parkinson’s disease is a neurodegenerative disorder with uncertain aetiology and ill-defined pathophysiology.
Activated microglial cells in the substantia nigra (SN) are found in all animal models of Parkinson’s disease
and patients with the illness. Microglia may, however, have detrimental and protective functions in this disease.
In this study, we tested the hypothesis that a sub-toxic dose of an inflammogen (lipopolysaccharide) can shift
microglia to a pro-inflammatory state and exacerbate disease progression in an animal model of Parkinson’s
disease.Central lipopolysaccharide injection in a degenerating SNexacerbated neurodegeneration, accelerated
and increased motor signs and shifted microglial activation towards a pro-inflammatory phenotype with
increased interleukin-1b (IL-1b) secretion. Glucocorticoid treatment and specific IL-1 inhibition reversed these
effects. Importantly, chronic systemic expression of IL-1 also exacerbated neurodegeneration and microglial
activation in the SN. In vitro, IL-1 directly exacerbated 6-OHDA-triggered dopaminergic toxicity. In vivo,w e
found that nitric oxide was a downstream molecule of IL-1action and partially responsible for the exacerbation
of neurodegeneration observed.Thus,IL-1exerts its exacerbating effect on degenerating dopaminergic neurons
by direct and indirect mechanisms.This work demonstrates an unequivocal association between IL-1 overpro-
duction and increased disease progression, pointing to inflammation as a risk factor for Parkinson’s disease and
suggesting that inflammation should be efficiently handled in patients to slow disease progression.
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Introduction
Parkinson’s disease is one of the most common progressive
neurodegenerative diseases, affecting over 1% of the popu-
lation over the age of 60. The main hallmark of the disease
is the progressive loss of dopaminergic neurons in the sub-
stantia nigra pars compacta (SN). Activated microglia are
found in the SN of Parkinson’s disease brains (McGeer
et al., 1988; Hunot et al., 1999; Hirsch et al., 2003; McGeer
and McGeer, 2004) and in animal models (Mirza et al.,
2000; Vila et al., 2001; Gao et al., 2002; Depino et al., 2003;
Ferrari et al., 2006); thus, inflammatory processes have also
been associated with the pathogenesis of the illness. An
alternative view however, is that microglia could increase
neuronal survival through the release of trophic and anti-
inflammatory factors (Vila et al., 2001; Hald and Lotharius,
2005). Whether microglial activation protects or exacerbates
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(Vila et al., 2001, Wu et al., 2002; Delgado and Ganea,
2003; Sanchez-Pernaute et al., 2004).
Microglial activation during neurodegeneration in
Parkinson’s disease and prion models was not found to
be accompanied by pro-inflammatory cytokine secretion
(Perry et al., 2002; Depino et al., 2003). However, we have
observed that microglial cells produced increased mRNA
levels of pro-inflammatory cytokines such as interleukin-1b
(IL-1b) during neurodegeneration in the SN, but that no
translation of these transcripts was observed (Depino et al.,
2003). These and other observations prompted the hypo-
thesis that these ‘atypical’ microglial cells are ‘primed’ cells.
Hypothetically, these ‘primed’ microglia cells could be
stimulated to adopt a potent neurotoxic pro-inflammatory
phenotype by a second stimulus and exacerbate neuro-
degeneration (Cunningham et al., 2005; McColl et al.,
2007). It is also well known that systemic inflammatory
mediators can induce the synthesis of cytokines within the
brain, suggesting that this second stimulus could have its
genesis in the periphery (Besedovsky and del Rey, 1996;
Pitossi et al., 1997).
Here we found that a second, pro-inflammatory stimulus
in the degenerating SN switches ‘primed’ microglia to a
pro-inflammatory phenotype, which leads to increased
neurodegeneration and earlier motor symptoms in a
Parkinson’s disease model. In addition, we have observed
increased IL-1b production when lipopolysaccharide (LPS)
was injected into the SN that has been previously exposed
to 6-hydroxydopamine (6-OHDA). The exacerbation of the
pro-inflammatory neurodegeneration and motor symptoms
were all inhibited by dexamethasone (DXM) and anti-
IL-1-specific treatments. Importantly, chronic, adenoviral-
mediated systemic IL-1 expression was also able to
exacerbate neurodegeneration in the SN, extending the
relevance of the effects of inflammation on neurodegenera-
tion to a more frequent scenario in the clinic. We also
showed that IL-1 could directly exacerbate 6-OHDA
toxicity to dopaminergic neurons in vitro. Finally, we
have observed that nitric oxide was induced downstream
from IL-1 production, and that its blockade partially inhi-
bited the exacerbation on neurodegeneration observed
in vivo. These last two results indicate that IL-1 is exerting
its exacerbating effect on 6-OHDA toxicity by direct and
indirect mechanisms.
Methods
Vectors
Adenoviral vectors were generated, quality controlled, and used as
described previously (Kolb et al., 2001; Ferrari et al., 2004; Battista
et al., 2006). Briefly, for construction of AdIL-1, human IL-1b
cDNA was cloned into a shuttle vector under the control of
a human cytomegalovirus promoter and co-transfected on
293 cells with a plasmid containing E1- to E3-deleted type 5
adenoviral genome. The correct recombination was verified
with restriction digestions of the purified viral DNA obtained
by HIRT. Stocks were obtained from large-scale preparations
in HEK293 cells by double cesium chloride gradients and
were quantified by plaque assay (final titers: Ad b-gal=5.56 
10
11pfu/ml, Ad IL-1=3.85 10
12pfu/ml, Ad IL-1ra=1.75 
10
12pfu/ml). Stocks had 51ng/ml of endotoxin, assayed with
E-TOXATE Reagents (Sigma, St Louis, Mi, USA). Viral
stocks were free of autoreplicative particles as assessed by
PCR and transduction of non-transcomplementary cells (HeLa,
ATCC). The adenoviral vector expressing b-galactosidase
(Adb-gal) was kindly provided by Dr J. Mallet (Hospital Pitie
Salpetriere, Paris).
Animals and surgical procedures
One hundred and seventy-eight adult male Wistar rats
(250–300g), were housed in groups of five animals, under
controlled temperature (22 2 C) and artificial light under a
12h cycle period and with water and food ad libitum. All animal
procedures were performed according to the rules and standards
of German animal law and the regulations for the use of
laboratory animals of the National Institute of Health, USA.
Animal experiments were approved by the Ethical Committee of
the Institute Leloir Foundation.
For stereotaxic injections, the animals were anaesthetized with
ketamine chlorhydrate (80mg/kg) and xylazine (8mg/kg) and
then injected in the left striatum with 20ug 6-OHDA (Sigma
dissolved in 4ul saline supplemented with 0.2mg/ml L-ascorbic
acid) or vehicle only, using a 10-ul Hamilton syringe. Twelve days
after they were injected, using 50mm tipped finely drawn glass
capillary containing 0.09mg lipopolysaccharide (LPS; strain
0111:B4, Sigma–Aldrich, MA, USA diluted in 2ml phosphate
buffer (PB) or vehicle in the left substantia nigra.
The stereotaxic coordinates of the left striatum were: bregma+
1.0mm; lateral+3.0mm; ventral –4.5mm (Depino et al., 2003)
and the coordinates of the left SN were bregma –5.3mm; lateral+
2mm; ventral –7.2mm) (Paxinos and Watson, 1986). Striatal
injections of 4ml 6-OHDA or vehicle were infused over 8min and
the needle tip kept in place for additional 2min before removal.
Nigral injections of 2ml LPS or vehicle were infused over 8min
and kept in place for additional 2min. The animals were killed at
21 days post-6-OHDA surgery.
The adenoviral injection took place three days before 6-OHDA.
The coordinates of the left MFB were: bregma –3.6mm; lateral+
2.0mm; ventral –8.6mm. (Paxinos and Watson, 1986). IL-1ra-
expressing and b-galactosidase-expressing adenoviral vectors were
diluted in sterile 10mM Tris–HCl, 1mM MgCl2 (pH=7.8) and
administered at a dose of 1 10
9pfu/rat.
The Dexamethasone group received a daily intraperitoneal
(i.p.) dose of Dexamethasone (1 10
–8M, Bruber Lab, Argentina)
beginning just after LPS or vehicle injection.
In order to assess the possible contribution of iNOS, a group of
animals were administered daily with 10mg/kg i.p. of a selective
and potent iNOS inhibitor S-methylisothiourea (SMT-Sigma,
Germany) beginning 15min before LPS or vehicle injection
(Iravani et al., 2002).
Systemic stimuli
Seven days after 6-OHDA was injected in the striatum, as
previously described, the animals were intravenously injected with
1.36 10
9pfu/rat of adenoviral vector producing human IL-1b or
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(pH=7.8) followed by 300ml of saline solution. Blood samples
were obtained from each group at day zero and at day twelve
to ascertain total leucocyte count.
Behavioural tests
Adjusting steps test
[Animals per group: 6-OHDA/LPS (9), 6-OHDA/Veh (6),
Veh/LPS (12), Veh/Veh (7), 6-OHDA/LPS+DXM (5), 6-OHDA/
Veh+DXM (5), Veh/LPS+DXM (4)]. This test was performed
according to Olsson et al. (1995) for assessment of akinaesia in
the unilateral Parkinson model. Briefly, the rat was held by the
experimenter with one hand fixing the hind limbs and slightly
raising the hind part above the surface with one paw touching the
surface. The animal was moved slowly sideways (5s for 0.9m),
first in the forehand (right–left direction) and then in the
backhand (left–right) direction for each paw. The sequence of
testing was right (contralateral) paw forehand and backhand
adjusting stepping, followed by left (ipsilateral) paw backhand and
forehand directions. The number of the steps was counted for
both paws in both directions. The experimenter handled rats at
least three times before surgery to familiarize the animal with the
test. In this period, animals are accustomed to the experimenter
and to the testing position. The last assay before surgery was
considered the pre-lesion stepping test.
Cylinder test
[Animals per group: 6-OHDA/LPS (9), 6-OHDA/Veh (8), Veh/
LPS (12) and Veh/Veh (8)]. Forelimb akinaesia was assessed using
the test described by Schallert et al. (1993). This test evaluates the
use of the forelimb to support the body against the walls of a
cylinder. To perform this test, the rats were put individually in
an acrylic cylinder (20cm 30cm). The test was performed
between 16:00 and 19:00h. The number of wall contacts
performed independently with the left and the right forepaw
were counted.
Histology
The animals were deeply anesthetized and transcardially perfused
with heparinized saline followed by cold 4% paraformaldehyde
in 0.1M phosphate buffer (PB) (pH=7.2). After removing the
brains, they were placed in the same fixative overnight at 4 C.
Then, the tissues were cryoprotected by immersion in 30%
sucrose, frozen in isopentane and serially sectioned in a cryostat
(40mm) throughout the SN in the coronal plane. The 40mm
sections were used either for cresyl violet staining or for free
floating immunohistochemistry.
Immunohistochemistry
Free-floating sections were incubated in blocking buffer (1%
donkey serum, 0.1% Triton in 0.1M PB) for 45min, rinsed in
0.1% Triton in 0.1M PB and incubated overnight with primary
antibodies diluted in blocking solution. The antibodies used
were: anti-Tyrosine hydroxylase (TH) for dopaminergic neurons
(diluted 1:1000; Chemicon, Temecula, CA, USA) anti ratIL-1b
(1:300; NIBSC, Potters Bar, UK), ED1 (1:200; Serotec, Raleigh,
NC), MHC II (Serotec, Raleigh, NC) and the biotinylated lectin
Griffonia simplicifolia (GSA-1B4, 1:100; Vector Laboratories,
Burlingame, CA, USA), for transforming microglial cells
(Kaur and Ling, 1991), GFAP (for astrocytes 1:700, DAKO),
anti-iNOS (1:100; Chemicon, UK) and anti-3-NT (1:100;
Upstate, USA). For immunohistochemical identification of
dopaminergic neurons, after three washes, the sections were
incubated with donkey-anti-rabbit-biotin-conjugated antibody
(Jackson, ImmunoResearch Laboratories Inc., West Grove, PA)
followed by Vectastain standard ABC kit (Vector Laboratories,
Burlingame, CA, USA) and developed with 3.30 diaminobenzidine
(Sigma, Saint Louis, MI, USA). Sections were mounted on DPX
(Fluka, Buchs, Switzerland). For double-labeling immuno-
histochemistry, after three 5min washes with 0.1M PB, the
sections were incubated with either indocarbocyanine Cy3 (Cy3)-
conjugated donkey anti-mouse antibody (1:250; Jackson
ImmunoResearch Laboratories Inc, West Grove, PA, USA),
cyanine Cy2 (Cy2)-conjugated donkey anti-rabbit antibody
(1:250; Jackson ImmunoResearch Laboratories, Inc, West Grove,
PA, USA) or Cy2 conjugated streptavidin (1:250; Jackson
ImmunoResearch Laboratories, Inc, West Grove, PA, USA) for
2h, rinsed in 0.1M PB and mounted in Mowiol (Calbiochem,
San Diego, CA, USA). Digital images were collected in a Zeiss
LSM 510 laser scanning confocal microscope equipped with a
krypton-argon laser.
Quantitation
Quantitation of dopaminergic neurons, TH- positive cells were
counted through the whole SN pars compacta at 20 magnifica-
tion. Every sixth 40-mm-thick section of each SN of every rat was
counted (from 8 to 10 sections per animal, usually nine sections
per rat). Sections were counted twice using double-blind
procedure. Graphs show the ratio between the ipsilateral hemi-
sphere versus the contralateral one [Animals per group for central
stimulus: 6-OHDA/LPS (7), 6-OHDA/Veh (9), Veh/LPS (5) and
Veh/Veh (4); central stimulus with DXM treatment 6-OHDA/
LPS+DXM (5), 6-OHDA/Veh+DXM (4), Veh/LPS+DXM (4)
and Veh/Veh+DXM (4); central stimulus with adenoviral inhibi-
tion of IL-1 Ad IL-1ra/6-OHDA/LPS (6), Ad b-gal/6-OHDA/LPS
(5), Ad IL-1ra/6-OHDA/Veh (4), Ad b-gal/6-OHDA/Veh (4),
Ad IL-1ra/Veh/LPS (4), Ad b-gal/Veh/LPS (4); systemic stimulus
6-OHDA/Ad IL-1biv(7), 6-OHDA/Ad b-gal iv (6), Veh/Ad
IL-1biv (9) and Veh/Ad b-gal iv (8)].
For the quantitation of MHCII positive cells, cells stage 4 were
identified by their morphology on MHCII staining under 40 
magnification and counted in every sixth 40-mm-thick serial
section of the SN of each rat using a double-blind procedure.
Graphs show the number of MHCII positive cells in the SN.
[Animals per group for central stimulus: 6-OHDA/LPS (4),
Veh/LPS (4); central stimulus with DXM treatment 6-OHDA/
LPS+DXM (3), Veh/LPS+DXM (3); central stimulus with
adenoviral inhibition of IL-1 Ad IL-1ra/6-OHDA/LPS (3),
Ad b-gal/6-OHDA/LPS (3), Ad IL-1ra/Veh/LPS (3), Ad b-gal/
Veh/LPS (3); systemic stimulus 6-OHDA/Ad IL-1biv(5),
6-OHDA/Ad b-gal iv (4), Veh/Ad IL-1biv (5) and Veh/Ad
b-gal iv (5)].
Classification of microglial activation
We adopted the classification of microglial activation according
to Kreutzberg (1996) Stages of microglia activation were
confirmed by observation by at least two different observers.
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stages of microglial activation.
Stage 1: Resting microglia. Rod shaped soma with fine and
ramified processes.
Stage 2: Activated ramified microglia. Elongated shaped cell body
with long and thicker processes.
Stage 3: Amoeboid microglia. Round shaped body with short,
thick and stout processes.
Stage 4: Phagocytic cells. Round shaped cells with vacuolated
cytoplasm, no processes can be observed at light microscopy level.
All these cellular types are GSA positive (GSA+). ED1 and
MHC-II are capable of staining activated but not resting microglia.
ELISA for IL-1b,T N FandI L -6
Animals were decapitated and their brains were quickly removed
and both the injected and non-injected SN were dissected, snap-
frozen in liquid nitrogen and stored at –80 C. Tissue was homo-
genized on ice in 400ml of Tris–HCl buffer (pH = 7.3) containing
protease inhibitors (10mg/ml aproteinin, 5mg/ml peptastin,
5mg/ml leupeptin, 1mM PMSF). Homogenates were centrifuged
at 10000g at 4 C for 10min and then ultracentrifuged at
40000r.p.m. for 2h. Samples were aliquoted and stored at
–80 C until use. Bradford protein assays were performed to deter-
mine total protein concentration in each sample. Commercially
available rat IL-1b, rat TNF-a and rat IL-6 kits (R&D,
Minneapolis, MN, USA) with high sensitivity were used to
quantify these cytokines according to the manufacturers’ instruc-
tions (15pg/ml for rIL-1b and 7.8pg/ml for rTNF-a and rIL-6).
Five to ten animals per group were analyzed and each sample
was in duplicate. To estimate protein recovery, rIL-1b standard
was added exogenously to brain homogenates and the ELISA was
performed as described before. A recovery of 85–90% of the added
rIL-1b standard was found. Animals per group: central stimulus
6-OHDA/LPS(10),6-OHDA/Veh(10),Veh/LPS(9)andVeh/Veh(7);
central stimulus with DXM treatment 6-OHDA/LPS+DXM (5) and
Veh/LPS+DXM (5); central stimulus with SMT treatment 6-OHDA/
LPS+SMT (6), 6-OHDA/Veh+SMT (6), Veh/LPS+SMT (6).
Neuronal cell cultures and cell viability
assay (MTT)
SK-N-SH (HTB-11, human brain neuroblastoma) cells were
cultured in RPMI 1640 (Gibco, Scotland, UK) supplemented
with 10% fetal bovine serum (Natocor). Cells were grown to
confluence at 37 Ci n5 %C O 2.
For mitochondrial tetrazolium assay (MTT) procedure, cells
were seeded 1 10
4cells/well in 96-well tissue culture plates.
Twenty-four hours later, cells were exposed to 6-OHDA solution
(3.125mM) diluted in culture medium. After 24h of incubation,
the medium was aspirated to be replaced by 100ml/well of
different concentrations of IL-1 (0.125, 0.0625, 0.05 and 0.03pg/ml)
and incubated for another 24h. Then, 10ml/well of MTT solution
(5mg/ml PBS) was added and incubated at 37 C for 4h. Finally,
100ml of isopropanol/0.04N HCl was added to each well. After
mixing thoroughly by repeated pipetting with a multichannel
pipettor, the plate was measured at 570nm using an ELISA
plate reader (BIO-RAD Model 550, microplate reader). The test
was carried out in two independent experiments, each tested in
triplicate.
RNA isolation, reverse transcription and
real-time PCR (RT-PCR)
Animals were decapitated and their brains were quickly removed
and both SN were dissected, snap-frozen in liquid nitrogen and
stored at –80 C. Total RNA was prepared by homogenizing nigral
tissue in 700ml of TRI Reagent (Sigma, USA). One microlitre of
Linear Acrylamide (5mg/ml) (Ambion) was added as a carrier and
the mixture was extracted with 140ml of chloroform. The aqueous
phase was precipitated with 400ml isopropanol and resuspended
in 20ml of RNAse-free milliQ water. Reverse transcription was
performed by incubating 10mg of the RNA with 1ml oligo-dT
(Invitrogen) and 1ml of SuperScript First-strand Synthesis System
for RT-PCR (Invitrogen), according to manufacturer’s protocol.
For quantitative RT-PCR reaction, 23ml of SYBR Green Master
Mix was added to 2ml of cDNA. The SYBR Green Master Mix
consisted of: 3mM MgCl2, 2.5mlo f1 0  PCR buffer, 0.3mM
dNTPs, 0.01mM Rox Dye, 0.1mg/ml BSA, 0.75mlo f1 0  SYBR
Green (Molecular Probes), 0.25ml Platinum Taq Polymerase
(Invitrogen, Life Technologies) and of either b2-microglobulin
or COX2, forward and reverse primers (0.2mM). Quantitative
RT-PCR was performed on an iCycler IQTM Real Time PCR
Detection System, (Bio-Rad). Reaction conditions were as follows:
2.5min at 94 C, 42 cycles of 45s at 94 C, 1min at 54 C, 1min at
72 C and 3min at 72 C. The specificity of PCR primers was
tested, and a single DNA band of the expected molecular size was
observed in a 1.5% agarose gel electrophoresis stained with
ethidium bromide. In addition, a single peak in the iCycler plot
was observed after a melting curve was performed. Primers for
b2-microglobulin were as follows forward, TCTTTCTGGTGCTTG
TCTC and reverse, AGTGTGAGCCAGGATGTAG and COX2
forward, TACCCGGACTGGATTCTACG and reverse, AAGTTGG
TGGGCTGTCAATC. Each sample was tested in triplicate. To
compare mRNA expression between treatments, the amount of
mRNA was expressed as the ratio of COX2/b2-microglobulin
levels.
Statistical analysis
Results are expressed as mean SEM in the different treatment
groups.
All experiments were analyzed by analysis of variance (ANOVA)
followed by Fisher’s protected least significant difference (LSD) as
post hoc test. To make sure parametric statistical analysis could be
carried out, all variables were tested for normality and variance
homogeneity with Kolmogorov–Smirnov and Levene test, respec-
tively. In two cases, data had to be transformed to conform to
these statistical requirements (Figs 4 and 6D).
The criteria used for the choice of statistical test to analyze the
data were determined by the number of factors present in the
experiment (Two or three-way ANOVA). When one of the levels
of any factor was missing, one-way ANOVA was performed con-
sidering each experimental group as a different treatment.
Three-way ANOVA and repeated measures (day) was used when
multiple measurements were performed on the same animal, as in
the case of the behavioural tests.
All post hoc test were carried out with Fisher’s protected LSD
test (least significant difference) and the level of statistical signi-
ficance was set at P50.05. For clarity, statistical analyses of each
test are addressed in each figure. All statistical tests were per-
formed using SPSS 11.0 for Windows (SPSS, Inc., Chicago, Il, USA).
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Central LPS administration exacerbates
ongoing 6-OHDA-mediated
neurodegeneration in the SN
To test whether inflammation can exacerbate ongoing neuro-
degeneration in the SN, we first injected different doses
(range 0.06–2mg) of lipopolysaccharide (LPS) into the SN
and observed that 0.09mg of LPS was able to produce
microglial activation without overt neurodegeneration in
that area (data not shown). Then, 12 days after injecting
animals with 6-OHDA or vehicle in the striatum (Sauer and
Oertel, 1994), we administered LPS or vehicle in the SN as
shown in Fig. 1A. This time point was chosen because
neurodegeneration has begun in the SN at 12 days and we
have previously found that microglial cells are ‘primed’ at
this point with increased pro-inflammatory cytokine tran-
scription, but without translation (Depino et al., 2003).
We quantified the surviving dopaminergic cells in the SN
in each experimental group 21 days after the 6-OHDA or
after vehicle injections (Fig. 2A) and found a statistically
significant decrease in the number of tyrosine hydroxylase
(TH) positive cells in the whole SN in animals treated
with 6-OHDA/LPS in comparison with the other groups
(6-OHDA/Veh, Veh/LPS, Veh/Veh) (Fig. 2A, P50.001).
There was no significant decrease in TH-positive cells when
comparing animals injected with LPS in an intact SN (Veh/
LPS) with the LPS control group (Veh/Veh) (Fig. 2A).
In particular, the combined treatment (neurodegenerative
and inflammatory) in the 6-OHDA/LPS group produced
more neurodegeneration (54.43%) than the effects of
the neurodegenerative treatment (6-OHDA/Veh) (31.67%)
and the inflammatory treatments separately (Veh/LPS)
(13.75%), indicating an exacerbating effect of the LPS on
the degenerating SN.
As a functional control of the exacerbating effect of LPS
on the ongoing neurodegeneration, we administered dexa-
methasone (DXM), a well-known anti-inflammatory ster-
oid, from days 12 to 20 to experimental groups described
(Fig. 1B). DXM treatment suppressed the reduction in
TH-positive cells in the SN in the 6-OHDA/LPS group up
to levels obtained in the 6-OHDA/Veh group (Fig. 2A,
P50.001 6-OHDA/LPS+DXM versus 6-OHDA/LPS-DXM).
There were no effects of DXM observed in the 6-OHDA/
Veh group suggesting that DXM had no effect on 6-OHDA
neurodegeneration per se. A marginal effect of DXM was
observed in the Veh/LPS group, attributable to a DXM-
mediated reduction of a minor local effect of LPS, the
Vehicle injection or both. This result suggests that DXM
treatment prevents the loss of TH-positive cells by blocking
the inflammation produced by LPS.
Central LPS administration exacerbates and
accelerates detectable 6-OHDA-mediated
motor deficits
In order to test whether the LPS-elicited inflammatory
reaction in the SN could exacerbate motor symptoms
Fig. 1 Timeline for central or systemic stimulus. Experimental groups were divided into: (A^C) ‘Central stimulus’ with rats intrastriatally
injected with 6-OHDA and LPS (6-OHDA/LPS) or vehicle (6-OHDA/Veh) at Day12 into the SN. Rats intrastriatally injected withVehicle
and LPS (Veh/LPS) or vehicle (Veh/Veh) at day 12 into the SN (A). (B) The dexamethasone (DXM) group received a daily intraperitoneal
dose of10
^8M of DXM starting just after the LPS or vehicle stereotaxical injection or10mg/kg of S-methylisothiourea SMT15min prior to
LPS or vehicle injection and daily after that. (C) In the IL1activity blockade experiments, animals were injected with Ad IL-1ra or Ad b-gal
in the MFB three days prior to 6-OHDA intrastriatal injection. (D) ‘Systemic stimulus’ with rats intrastriatally injected with 6-OHDA and
intravenously with Ad IL1b (6-OHDA/Ad IL1biv) or vehicle (6-OHDA/Ad b-gal iv) at Day 7 in the tail vein. Rats intrastriatally injected
with Vehicle and intravenously with Ad IL1b (Veh/Ad IL1biv) or Ad b-gal (Veh/Ad b-gal iv) in the tail vein.
1884 Brain (2008),131,1880^1894 M.C. P.Godoy et al.Fig. 2 (A) Remaining number of TH positive cells in the SN 21days after different central treatments.Quantitation of TH positive cells as
a percentage of cells in the ipsilateral hemisphere versus the contralateral one.Two-way ANOVA (significant double interaction P50.05)
was followed by Fisher’s LSD post hoc test.    P50.0016-OHDA/LPS compared to 6-OHDA/Veh,Veh/LPS and Veh/Veh group.   P50.01
6-OHDA/Veh compared toVeh/LPS.    P50.0016-OHDA/Veh compared toVeh/Veh. Error bars represent SEM. (N=7 ,9, 5 and 4 for
6-OHDA/LPS, 6-OHDA/Veh,Veh/LPS and Veh/Veh groups, respectively). DXM group:Three-way ANOVA (significant triple interaction
P50.01) was followed by Fisher’s LSD post ^hoc test.
   P50.001 significant difference between 6-OHDA/LPS+DXM and 6-OHDA/LPS-
DXM.
 P50.05 significant difference betweenVeh/LPS+DXM and Veh/LPS-DXM.Error bars represent SEM. (N=5 ,4 ,4a n d4f o r6-O H D A /
LPS+DXM, 6-OHDA/Veh+DXM,Veh/LPS+DXM and Veh/Veh+DXM groups, respectively). SMT group: One-way ANOVAwas followed by
Fisher’s LSD post hoc test.
gggP50.001significant difference between 6-OHDA/LPS+SMTand 6-OHDA/LPS-SMT .
gP50.05 significant dif-
ference between 6-OHDA/LPS+SMTand 6-OHDA/Veh+SMT .Error bars represent SEM. (N= 6, 4 and 5 for 6-OHDA/LPS+SMT, 6-OHDA/
Veh+SMT and Veh/LPS+SMT groups, respectively). (B and C) Motor behavioural deficits after central treatments and the effects of anti-
inflammatory agentonbehavioural tests. (B) Cylinder test.The number of firstpaw placementon the surface of a cylinder was counted for
each experimental group.Three-way ANOVA (significant striatumçpaw double interaction P50.001) was followed by Fisher’s LSD post
hoc test.    P50.001when comparing 6-OHDA/LPS between left and right paws.   P50.01when comparing 6-OHDA/Veh between left
and right paws. Error bars represent SEM. (N=9, 8,12 and 8 for 6-OHDA/LPS, 6-OHDA/Veh,Veh/LPS and Veh/Veh groups, respectively).
(C) Adjusting steps test at15 and 20 days after 6-OHDA or Vehicle injection (pre-lesion measurements were carried out for every animal).
Performance with the left paw (ipsilateral to the lesion) presented no difference in both directions (data not shown).Only performance
with the right paw was impaired in both directions (backhand direction not shown).Three-way ANOVA (Striatum, SN and day with
repeated measures for the last factor) was followed by Fisher’s LSD post hoc test.   P50.01, significant difference between 6-OHDA/LPS
group and the pre-lesion measurement.   P50.01significant difference among 6-OHDA/LPS group and other groups (6-OHDA/Veh,Veh/
LPS and Veh/Veh) within the same time point.
iP50.05 difference among 6-OHDA/Veh group and other controlgroups (Veh/LPS and Veh/
Veh) for Day 20.
gP50.05 significant difference between 6-OHDA/LPS group with or without DXM treatment at each time point (Day15
and Day 20). Error bars represent SEM. (N= 9, 6, 12, 7, 5, 5 and 4 for 6-OHDA/LPS, 6-OHDA/Veh, Veh/LPS, Veh/Veh, 6-OHDA/LPS+DXM,
6-OHDA/Veh+DXM,Veh/LPS+DXM groups, respectively).
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were performed during the period of ongoing neuro-
degeneration.
Cylinder test
The treatment with 6-OHDA produced a marked and
statistically significant difference in the placement of the
contralateral paw on the cylinder’s surface that was inde-
pendent of other treatments (Fig. 2B, 6-OHDA/LPS and
6-OHDA/Vehicle versus the other two groups, P50.001
when comparing 6-OHDA/LPS between left and right paws,
P50.01 when comparing 6-OHDA/Veh between left and
right paws). The total number of first paw placements was
not altered between groups (Fig. 2B). Thus, this test was
very sensitive to the 6-OHDA effect independently of any
subsequent treatment.
Adjusting steps test
At 15 days, the 6-OHDA/LPS group, but not any of the
other groups, showed a significant decrease in the number
of adjusting steps with the right paw (contralateral to the
lesion) in both directions (Fig. 2C,   P50.01 when
compared 6-OHDA/LPS to pre-lesion measurement,
  P50.01 when compared 6-OHDA/LPS to other groups,
backhand direction not shown). Thus, the effect of the
administration of LPS in the SN on the 6-OHDA-injected
animals elicited motor disabilities sooner than in the other
groups. In addition, at 20 days post 6-OHDA inoculation,
the 6-OHDA/LPS animals showed increased motor dis-
abilities when compared to the 6-OHDA/Veh group
(Fig. 2C,   P50.01). This result suggests that LPS elicited
motor disabilities earlier in the pathogenesis and also
increased motor symptoms, in agreement with the increased
neurodegeneration observed previously in this group. The
Veh/LPS and Veh/Veh groups showed no motor impair-
ments (Fig. 2C), as expected from the number of TH-
positive cells in the SN remaining in each animal at that
time point. Thus this test demonstrated the exacerbation of
motor symptoms in the 6-OHDA/LPS treated group.
In order to address the question as to whether the
attenuation of inflammation could prevent the exacerbation
of motor symptoms, we performed the same behavioural
test with the same DXM treatment as described previously.
Dyskinaesia associated with LPS-triggered exacerbation was
reversed in animals treated with DXM (Fig. 2C,
gP50.05
6-OHDA/LPS+DXM versus 6-OHDA/LPS-DXM). The
number of adjustment steps in the 6-OHDA/LPS group
increased with respect to the same group without DXM up
to the level of 6-OHDA/Veh group. This result was again in
agreement with the number of TH-positive cells remaining.
As expected, there were no differences in the control groups
after DXM treatment (6-OHDA/Veh, Veh/LPS-Fig. 2C).
These results provide functional evidence that the LPS-
triggered inflammation resulted in exacerbation of motor
disabilities in the 6-OHDA-treated animals.
Primed microglial cells are markedly
shifted to a pro-inflammatory stage in
the 6-OHDA/LPS animals only
Microglial cells are the main modulators of inflammation in
the brain. In the 6-OHDA model, activated microglial cells
exhibit morphological changes defined as stage 3, but not
stage 4 (Depino et al., 2003). We studied the morphological
changes associated with microglial activation by staining
with the microglia marker Griffonia Simplicifolia Lectin I
Isolectin B4 (GSA) and by the detection of specific markers
such as ED-1 and MHC class II expression. In animals
treated with 6-OHDA/LPS, mainly stage 4, ED-1-positive
microglia was visualized by GSA-staining in the whole SN.
(Fig. 3A and D, see yellow circles for a higher magnification
and detailed description of microglial activation (Fig. 3A0,
A00 and A000). MHC class II-positive cells showed similar
morphological stages of activation to GSA labelling, but
the distribution of the label was more restricted to the
lesion (Fig. 3G). In contrast, only stages 2–3 of microglial
phenotype with sparse ED-1 and MHC II-reactivity along
the injection tract were observed in the SN of 6OHDA/Veh
group (Fig. 3B, E and H and data not shown). In the
animals injected with LPS only in the SN (Veh/LPS), the
vast majority of microglia presented morphology consistent
with stage 2 or 3 while stage 4, ED-1 and MHCII-positive
cells were rare and only observed at the injection site
(Fig. 3C, F and I). Thus, this dose of LPS could only
marginally drive microglia phenotype to stage 4at the
injection site (5240mm rostrocaudally within the SN), but
the same LPS dose injected into rats previously treated with
6-OHDA led to a massive change of microglial morphology
(mainly stage 4at least 1920mm across the SN). Rats treated
with Veh/Veh, showed minor microglial phenotype changes
(stages 1–2) at the capillary tract. Thus, these data suggest
that only LPS administration in the neurodegenerating
SN shifted the microglial phenotype to stage 4, ED-1,
MHCII-positive cells.
We also studied the potential involvement of astrocytes
by performing immunohistochemistry against GFAP in
the SN of 6-OHDA/LPS, 6-OHDA/Veh, Veh/LPS animals.
We found no induced expression of GFAP in the SN pars
compacta of any experimental group, suggesting a minor
participation of astrocytes in the exacerbating effect of LPS
and highlighting the relevance of microglial activation in
this model (data not shown).
It is known that DXM treatment downregulates micro-
glial activation and, in particular, MHC class II expression
in microglial cells in vitro and in vivo (Kiefer and
Kreutzberg, 1991). DXM treatment reduced MHC class II
expression in animals treated with 6OHDA/LPS or Veh/LPS
(Fig. 3, compare G and I with N and O, respectively). The
number of stage 4, MHC class II-positive cells was reduced
by 450% after DXM treatment (Fig. 3P,   P50.01
6-OHDA/LPS+DXM versus 6-OHDA/LPS-DXM). By con-
trast, GSA and ED-1 staining seemed to be not altered with
1886 Brain (2008),131,1880^1894 M.C.P.Godoyet al.the DXM treatment (Fig. 3 compare A versus J and C
versus K for GSA profile and D versus L and F versus M
for ED-1 profile). These results identify a distinct popula-
tion of activated microglial cells (MHCII-positive), that
correlate with the levels of neurodegeneration and motor
symptoms in the 6-OHDA/LPS group before and after
DXM treatment.
The pro-inflammatory stage of microglial activation is
best defined by the molecules secreted, such as the pro-
inflammatory cytokines. We investigated the expression
profile of three key pro-inflammatory cytokines; IL-1b,
TNFa and IL-6 in the SN of rats from each experimental
group at 21 days post-6-OHDA, the same time point when
neurodegeneration, motor symptoms and microglial activa-
tion were examined. Interestingly, we found, using ELISA,
a significant increase in the induction of IL-1b expression
in rats treated with 6-OHDA/LPS in comparison with the
Fig. 3 Activation of microglial cells in the SN after different
central treatments (A^I) DXM-treated groups are also shown
(J^P).( A^C). Activation of microglial cells as demonstrated by
GSA (green)/TH (red). (A). Animals injected with 6-OHDA/LPS
mostly exhibited GSA+cells at stage 4. In addition stages 2^3
microglial cells can be observed surrounding the SNpc.The
animals injected with 6-OHDA/Veh (B)a n dV e h / L P S( C)h a v e
GSA+cells at stages 2 and 3 in the SN. A0^A000:E x a m p l e so f
different stages of microglial activation magnified from A (yellow
circles): A0, Stage 2 characteristic rod-shaped cell.Ramified pro-
cesses can bevisualized; A00, Stage 3 amoeboid microglia with thick
and stout processes; A000 Stage 4 Phagocytic cell, round-shaped
body. (D^F). Activated microglia with macrophage characteristics
confirmed by ED1 (green), in the SN labelled withTH (red) immu-
nofluorescence. (D). ED1+cells at stage 2, 3 and 4 are observed
within the SN in the 6-OHDA/LPS group. However, control
groups (6-OHDA/Veh and Veh/LPS) exhibited scarce ED1labelling
(E and F, respectively). (G^I). Expression of the class two
major histocompatibility complex (MHC-II) (red) and rat IL-1b
(rIL-1b green) in the different treatments. (G). Stage 4 MHC-
II+cells are observed within the SN but ramified MHC-II+cells
are located surrounding the lesion in 6-OHDA/LPS group.
Ramified rIL-1b+cells are also observed within the lesion in this
group (G). (H) Animals treated with 6-OHDA/Veh showed
MHC-II+cells at stage 2. No IL-1blabel was observed in this
group. (I) Some MHC-II+cells at stage 4 can be observed at the
injection site inVeh/LPS group. Stages 2 and 3 cells were also
observed surrounding the injection site.Ramified rIL-1b+cel lscan
also be seen in the same region. (J^P) Microglial activation after
Dexamethasone treatment. (J and K) Activation of microglial cells
demonstrated by GSA (green)/in the SN labeled withTH (red)
staining. (J) The animals injected with 6-OHDA/LPS and treated
with DXM showed mostly stage 4 GSA+cells in the whole SN.
However, the Veh/LPS DXM treated group exhibited stage 2^3
microglial cells in the SN (K). J0^J000: Examples of different stages of
microglial activation magnified from J (yellow circles): J0,S t a g e2
characteristic rod-shaped cell.Ramified processes can be visua-
lized; J00, Stage 3 amoeboid microglia with thick and stout pro-
cesses; J000 Stage 4 Phagocytic cell, round-shaped body. Scale bar
A0,A 00,A 000 and J0,J 00,J 000:2 0mm. (L and M) Activated microglia
with macrophage characteristics confirmed by ED1(green)
immunofluorescence. (L) 6-OHDA/LPS DXM treated group
showed ED-1+cells at stage 4 within the lesion site, but also
exhibited microglial cells at stage 2 and 3 surrounding the SN. The
control group,Veh/LPS treated with DXM mainly had ED-1+cells
at stages 2^3, but scarce cells at stage 4 can also be observed (M).
(N^P). Expression of the major histocompatibility complex class
two (MHC-II) (red) and rIL-1b (rat IL-1b green) in DXM treat-
ment. (N) The animals injected with 6-OHDA/LPS and DXM
exhibited less MHC-II label than those observed in non-DXM-
treated animals (G). Some cells reached stage 4, but most of them
were at stages 2^3 (N). Ramified IL-1b+cells can also be observed
within the lesion (N). (O) Stages 2 and 3 MHC-II+cells were
observed in the SN of animals injected withVeh/LPS and DXM.No
IL-1blabel was observed in this group. Scale bar:100mm. (P)
Number of MHC-II+cells at stage 4 in the SN of animals injected
with 6-OHDA/LPS (N=4) ,V eh /LPS( N= 4), 6-OHDA/LPS +DXM
(N=3)andV eh /LPS+D X M( N=3) .T wo-wa yAN O V A(s i gnificant
double interaction P50.05) followed by Fisher0sL S Dpost hoc test.
  P50.01 6-OHDA/LPS+DXM compared to 6-OHDA/LPS-DXM.
Error bars represent SEM.
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(Fig. 4, P50.001). No differences were found between the
6-OHDA/Veh, Veh/LPS and Veh/Veh groups. Immunohis-
tochemical analysis confirmed the presence of ramified rat
IL1b (rIL-1b) positive cells in the whole SN of 6-OHDA/LPS
injected animals (Fig. 3G). On the contrary, rIL1b positive
cells were scarce and found only at the injection site or
along the capillary tract in the Veh/LPS and 6-OHDA/Veh
groups respectively (Fig. 3I and H).
There were no differences in the levels of TNFa or IL
6 protein in the SN of any group (data not shown). Thus,
neither of these cytokines appears to be involved in the
exacerbating effects observed in the 6-OHDA/LPS animals.
IL-1b expression was markedly diminished in the
6-OHDA/LPS group with DXM treatment compared with
the same group without DXM administration (Fig. 4), with
levels comparable to all other experimental control groups
(Fig. 4). Thus, DXM was able to inhibit the exacerbation on
IL-1b synthesis by LPS on 6-OHDA-affected SN.
Inhibition of IL-1 activity in the SN
leads to decreased neurodegeneration
but not downregulation of microglial
activation in that region
To confirm IL-1b participation in the exacerbation of the
ongoing neurodegeneration by LPS, we decided to block
IL1b biological activity by injecting an adenovirus expres-
sing the natural endogenous inhibitor of IL-1, IL-1ra in the
SN (Fig. 1C). We chose to inject the viral vector in the
medial forebrain bundle (MFB) in order to induce IL-1ra in
the SN without injecting this area twice. We know from
previous results that the efficiency of transduction with
control adenoviral vectors using this route of injection
amounted to 30–35% of TH+ cells in the SN, leaving the
SN undisturbed (data not shown). In addition, under our
experimental conditions, no adenoviral vector mediated
inflammation is observed in the brain 7 days after vector
inoculation (Ferrari et al., 2006) and this vector can
efficiently inhibit IL-1 activity (Depino et al., 2004).
The injection of 1 10
9pfu of adenovirus expressing IL-
1ra in the MFB of 6-OHDA/LPS animals lead to an increase
in TH-positive cells in the SN when compared with similar
animals injected with 1 10
9pfu of an adenovector expres-
sing b-galactosidase (Fig. 5A, P50.001). This rise in the
number of TH-positive cells was comparable to the number
of TH-positive cells left after the 6-OHDA treatment alone.
No changes were seen in the 6-OHDA/Veh group as
expected because of the lack of induction of IL-1b in this
group (Fig. 5A). As expected, the AdIL-1ra treatment had
no effect on the number of dopaminergic neurons in the
SN of Veh/LPS animals (Fig. 5A), since this dose of LPS
was not neurodegenerative per se (Fig. 2A). These results
point to IL-1 as a key mediator of LPS-mediated exacer-
bation of neuronal loss in the degenerating SN.
IL-1-induced functional blockade did not show any effects
on the stages of microglial activation in the 6-OHDA/LPS
group as seen by morphological changes detected by GSA
staining (Fig. 5B), ED1 immunolabelling (Fig. 5D) or MHC
class II expression (Fig. 5F and H) in the SN. No effects
were observed in the Veh/LPS group (Fig. 5C, E, G and H).
These results suggest that IL-1b expression is a downstream
event from microglial activation.
Systemic, chronic IL-1 expression exacerbated
6-O H D A-mediatedneurodegeneration
and drove microglia to end-stage
activation in the SN
We generated an animal model of chronic systemic inflam-
mation by injecting an adenoviral vector expressing IL1b
(or b-galactosidase as control) in the tail vein of 6-OHDA
Fig. 4 IL-1bexpression measured by ELISA in the SN after different treatments.Two-way ANOVA (Striatum and SN) with significant
double interaction P50.05 was followed by Fisher’s LSD post hoc test.    P50.001 6-OHDA/LPS (N=10) compared to 6-OHDA/Veh
(N=1 0) ,V eh /LPS( N=9)andV eh /V eh( N=7).DXM group: IL-1content in the SN by ELISAwas also measured for Dexamethasone-treated
animals (6-OHDA/LPS+DXM N=5andV eh /LPS+D X MN=5).Two-way ANOVA (Striatum and DXM) with significant double interaction
P50.05 was followed by Fisher’s LSD post hoc test. P50.05 significant difference between 6-OHDA/LPS group with or without DXM
treatment. Error bars represent SEM. SMT group: ELISAwas also used to measure IL-1in the SN of SMT-treated animals. (6-OHDA/LPS,
6-OHDA/Veh, Veh/LPS N=6 for each group). After a one-way ANOVA no statistical difference was found between groups with or
without SMT treatment.    P50.0016-OHDA/LPS+SMT compared to 6-OHDA/Veh+SMTand Veh/LPS +SMT .The minimal amount of IL-1
depicted in the graph represents the detection threshold of the assay.
1888 Brain (2008),131,1880^1894 M.C. P.Godoy et al.Fig. 5 Inhibition of IL-1bactivity. (A) Quantitation of remainingTH-positive cells as a percentage of cells in the ipsilateral hemisphere
versus the contralateral one. Ad IL-1ra-treated rats: filled bars, Adb-gal-treated rats: empty bars. Significant differences were analyzed
with one-way ANOVA.    P50.001 significant difference between 6OHDA/LPS group treated with Ad IL-1ra or with control adenovirus
(Ad b-gal). (Ad IL-1ra/6-OHDA/LPS N=6,Adb-gal/6-OHDA/LPS N=5 ,al lot he rg roupsN=4). Error bars represent SEM. (B^G)
Microglial activation after AdIL-1ra treatment. (B and C) Microglial activation evidenced with GSA (green) in the SN labeled withTH (red).
(B) Morphological activation at Stage 4 was observed in the SN of animals injected with 6-OHDA/LPS and treated with AdIL-1ra. Some
stage 3 cells canbe observed surrounding the SNpc. (C) Control animals injected withVeh/LPS and AdIL-1ra exhibited few GSA+ cells only
at stages 2^3. (D and E). Phagocytic activity evidenced by ED-1immunolabelling (green). (F and G). Expression of the class two major
histocompatibility complex (MHC-II) (red) and rIL-1b (rat IL-1b^green) after AdIL-1ra treatment in 6-OHDA/LPS and Veh/LPS animals.
(F) The SN of 6-OHDA/LPS + AdIL-1ra animals showed mostly stage 4 MHC-II+ cells. Ramified rIL-1b+cells were observed surrounding
the lesion. (G) The SN of control animals exhibited a reduced number of MHC-II + and IL-1b+ cells at the injection site. Scale bar:100mm.
B0,B 00,C 0,C 00: Examples of different stages of microglial activation magnified from B and C (yellow circles): B0, Stage 3 amoeboid microglia
with thick and stout processes; B00, Stage 4 phagocytic cell, round-shaped body; C0, Stage 2 rod-shaped cell and C00,S t a g e3a m o e b o i d
microglia. Scale bar B0,B 00,C 0,C 00:2 0mm. (H) Quantitation of MHCII positive cells (stage 4) throughout the SN 21days after 6-OHDA in
animals with IL-1activity inhibited (Ad IL-1ra ^ dark grey bars) or controls [Ad b-gal (light grey bars) or no Ad treatment (black bars)].
No statistically significant differences were found between the different treatments. (AdIL-1ra/6-OHDA/LPS N=3 ,Adb-gal/6-OHDA/LPS
N=3 ,AdI L -1 ra/V eh /LPSN=3 ,Adb-gal/Veh/LPS N=3). Error bars represent SEM.
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(Fig. 1). We chose this time point since we knew that IL-1
triggered inflammation in the periphery normally lasts for
at least 5 days, impacting in the SN at similar time points
(ca. 12 days post-6-OHDA) as in the other experimental
set-ups (Fig. 1D). As a control for the systemic effects of
AdIL-1, a total leucocyte count was made on blood samples
taken five days after adenoviral injection but not on Day
zero and compared to Ad b-gal injected animals (data not
shown).
Interestingly, a statistically significant decrease in the
number of TH-positive cells in the SN was observed in the
animals treated with 6-OHDA/Ad IL1biv in comparison
with the other groups (Fig. 6A, P50.05 6-OHDA/Ad
IL1biv compared to 6-OHDA/Ad b-gal iv). No direct effect
of systemic IL-1 was observed in animals with an intact SN
(Veh/Ad IL-1 iv) suggesting that systemic IL-1 expression
can exacerbate, but not directly elicit, neurodegeneration
in the SN.
In addition, animals injected with 6-OHDA in the
striatum and AdIL1b intravenously were the only ones to
show stage 4 morphology by GSA-lectin staining (Fig. 6B)
and ED1 immunoreactivity throughout the SN (Fig. 6C). A
statistically significant difference in the amount of MHCII-
positive cells was found between the 6-OHDA/Ad IL-1 iv
group and the control groups (Fig. 6D, P50.01).
IL-1 exacerbates neurodegeneration
directly and via nitric oxide
To address the question of whether IL-1 is directly toxic to
neurons, we used an in vitro cell culture model to exacer-
bate the effects of IL-1 observed previously in vivo.
A human neuronal cell line was treated with 3.125mM
6-OHDA and 1day later, escalating non-toxic doses of IL-1
were added to the medium to see if this second treatment
had any effect on the viability of the cells. The addition of
IL-1 from 0.125 to 0.03pg/ml had no effect per se on cell
viability (percentage of viability 96.3% for 0.125pg/ml,
97.5% for 0.0625pg/ml, 95.54% for 0.05pg/ml and 102.3%
for 0.03pg/ml, data not shown), but the three highest doses
produced an exacerbating effect on 6-OHDA toxicity
(Fig. 7A). Thus, we conclude that IL-1 is able to act
directly on neurons and exacerbates 6-OHDA-triggered
neuronal death.
We then investigated the role of other possible IL-1-
induced molecules as possible mediators of IL-1 action.
We studied the relevance of nitric oxide (NO) in this model
by investigating iNOS expression and the appearance
of nitrotyrosine (3-NT) immunoreactivity in the SN of
6-OHDA/LPS, 6-OHDA/Vehicle or Veh/LPS animals by
immunohistochemistry. iNOS expression and 3-NT were
detected almost exclusively on sections from 6-OHDA/LPS
animals, suggesting a differential expression of NO in that
group of animals (Fig. 7B and C).
This result prompted us to test the functional relevance
of this differential NO expression on dopaminergic cell loss
in our experimental groups. Thus, 6-OHDA/LPS, 6-OHDA/
Veh and Veh/LPS animals were treated i.p. with 10mg/kg
Fig. 6 Systemic Ad IL-1binjection increased neuronal loss in the
SN. (A) Remaining number of TH-positive cells in the SN after
systemic injection.Quantitation of TH-positive cells as a percen-
tage of cells in the ipsilateral hemisphere versus the contralateral
one.Two-way ANOVA (Striatum and systemic stimulus) with sig-
nificant double interaction P50.05 was followed by Fisher’s LSD
post hoc test.  P50.05, compare 6-OHDA/Ad IL-1biv (N=7)to
6-OHDA/Ad b-gal iv (N=6) .N=9 and 8 for Veh/Ad IL-1biv and
Veh/Ad b-gal iv groups, respectively). Error bars represent SEM.
(B and C) Microglial activation in the SN of animals injected
with 6-OHDA/Ad IL-1bi.v. B. GSA-positive (B) and ED-1-positive
(C) cells at stage 4 were observed in the SN of 6-OHDA/AdIL-
1bi.v. Scale bar B: 50 mm. Scale bar C:100mm. Inset in B (B’):
magnification showing a stage 4 activated microglial cell. Scale bar
inset (B’):10mm. (D) Quantitation of MHCII positive cells through-
out the SN after systemic challenge.Two-way ANOVA (Striatum
and systemic stimulus) with significant double interaction P50.01
was followed by Fisher’s LSD post hoc test.   P50.01significant
difference between 6-OHDA/Ad IL-1biv compared to every other
groups. N=5 ,4 ,5a n d5f o r6- O H D A / A dI L - 1 biv 6-OHDA/Ad
b-gal iv,Veh/Ad IL-1biv and Veh/Ad b-gal iv groups, respectively.
Error bars represent SEM.
1890 Brain (2008),131,1880^1894 M.C. P.Godoy et al.of S-methylisothiourea (SMT) (Iravani et al., 2002), a
potent iNOS inhibitor, daily from the moment of the
second stimulus (Day 12) till the day of sacrifice and TH-
positive neurons were counted throughout the SN (Fig. 1).
As expected, no expression of iNOS and 3-NT was found
in the SMT-treated animals by immunohistochemistry
(Fig. 7H and I). Only the 6-OHDA/LPS animals showed
an increased number of TH-positive neurons in the SN
after the SMT treatment, partially reversing the exacerbating
effect of LPS (Fig. 2A). This inhibition of LPS action was
not total since the values of TH-positive neurons in the
6-OHDA/LPS+SMT were significantly lower to the ones of
the 6-OHDA/Veh+SMT group (P50.05) (Fig. 2A). These
results suggest a main, but not exclusive participation of
NO in the LPS exacerbating effect.
Then, we studied whether IL-1 expression was upstream
of NO induction in our model of Parkinson’s disease
exacerbation. In order to address this issue, we studied
whether the levels of IL-1 in the SN were affected by the
inhibition of NO after the SMT treatment by ELISA. The
changes in IL-1 levels were only marginally and not signi-
ficantly altered by the SMT treatment in the 6-OHDA/LPS
Fig. 7 (A) Viability of SK-N-SH cells tested by MTTassay.Cells were pre-treated with 6-OHDA and subjected to escalating doses of IL-1.
Concentration-dependent decreases in cell viability in response to IL-1were observed.One-way ANOVA followed by Fisher’s LSD post hoc
test.   P50.01significant difference between 3.125mM 6-OHDA/0.0125 pg/mlo fI L - 1a n d3 . 1 2 5mM 6-OHDA/0 pg/mlo fI L - 1 . P50.05
significant difference between 3.125mM 6-OHDA/0.0625 pg/mlo fI L - 1o r3 . 1 2 5mM 6-OHDA/0.05 pg/mlo fI L - 1a n d3 . 1 2 5mM 6-OHDA/0 pg/ml
of IL-1. Every group was normalized to100%. Error bars represent SEM. (B^I) iNOS expression and 3-NT immunohistochemistry in
different animal groups. (B and C).RamifiediNOS and 3-NT positive cells were observed within the SN of 6-OHDA/LPS-treated animals.
(D and E) 6-OHDA/Veh animal group was completely devoid of iNOS and 3-NT immunoreactivity. (F and G) Veh/LPS animals exhibited
a reduced immunoreactivity of ramified iNOS positive cells at the injection site. No 3-NT label was observed in this group. (H and I)
No iNOS expression or 3-NT immunoreactivity was observed in the 6-OHDA/LPS+SMT-treated group. Scale bar:100mm.
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and without SMT treatment), suggesting that NO produc-
tion was downstream of IL-1 induction after the admin-
istration of LPS in the 6-OHDA animals.
In addition, to investigate the possible involvement
of prostaglandins, we have studied the expression of
cyclooxygenase-2 (COX-2) by RT-PCR on RNA samples
from the SN of 6-OHDA/LPS, 6-OHDA/Veh- and Veh/
LPS-treated animals. No differences in COX-2 expression
were detected among the different experimental groups
(data not shown).
Taking all these results together, we conclude that the
most probable scenario is that IL-1 is acting both directly
on neurons and indirectly via NO and possibly other
unidentified molecules.
Discussion
In this study, we show for the first time that a sub-toxic
dose of LPS injected in the degenerating SN exacerbates
neuronal loss, shifts microglial activation to a pro-
inflammatory phenotype, increases IL-1b production, and,
importantly, produces earlier and increased motor dis-
abilities compared to 6-OHDA-only treated animals. In
addition, a common and widely used anti-inflammatory
agent, DXM, was able to reverse the exacerbating effects of
LPS. Furthermore, we demonstrate that IL-1 plays a major
role in this exacerbation. Finally, chronic systemic expres-
sion of IL-1 was able to exacerbate neuronal demise and
microglial activation in the SN, increasing the clinical
impact of these findings. Evidence was found for direct and
indirect effects of IL-1 on the exacerbation of 6-OHDA
toxicity on dopaminergic neurons.
Inflammation can exacerbate
neurodegeneration and motor symptoms in
Parkinson’s disease
Our results show that LPS can exacerbate neurodegenera-
tion in the SN and aggravate and accelerate the appearance
of behavioural symptoms in our Parkinson’s disease model.
Similar effects on neuronal loss were observed in animals
where chronic, systemic inflammation was evoked. These
results suggest that systemic or central inflammation
could be regarded as a risk factor for the exacerbation of
Parkinson’s disease.
Inflammation has been ubiquitously found in the SN of
animal models and Parkinson’s disease patients. Infections
such as influenza virus, Helicobacter pylori, HIV and even
candidiasis and their accompanying inflammatory responses
have also been suggested, but not proven, as etiological
agents of Parkinson’s disease (Arai et al., 2006; Epp and
Mravec, 2006). Specially, a case supporting the correlation
between a major increase in parkinsonian symptoms and
the influenza pandemic of 1918 has been widely discussed
(Isgreen et al., 1976; Ravenholt and Foege, 1982; Takahashi
and Yamada, 1999; Marttila and Rinne, 1976). In light of
our results that inflammation can accelerate the appearance
of Parkinson’s disease symptoms, it is possible to argue that
infections can exacerbate an ongoing neurodegeneration in
the SN of otherwise asymptomatic patients, rendering them
symptomatic and thus, clinically defined as Parkinson’s
disease patients. On the other hand, the long-term expres-
sion of IL-1 in the periphery by adenoviral vectors did not
cause overt neurodegeneration per se, indicating the need
for a second event (i.e. an ongoing degeneration in the SN)
to observe a toxic effect of systemic inflammation. Thus,
although our data do not reject infections as etiological
agents of Parkinson’s disease, we favour the idea of inflam-
mation as an exacerbating agent of Parkinson’s disease.
Mechanisms of inflammation-triggered
PD exacerbation
Whether microglial activation protects or exacerbates
neuronal loss in the SN has been intensively debated
(Vila et al., 2001; Nagatsu, 2002; Hirsch et al., 2003, 2005;
Block and Hong, 2005; Hald and Lotharius, 2005; Kim and
de Vellis, 2005). Microglial cells can be activated to dif-
ferent stages according to morphology, expressed markers
and secreted products (Perry et al., 2007). Morphological
characteristics and cellular markers can be misleading in
terms of the functional effect of activated microglia on
neuronal demise (Perry et al., 2007). In our study, stage 4
microglia and MHC II expression was associated with
exacerbated neurodegeneration and motor symptoms.
Whether this correlation is unique to our model or not,
deserves future investigation. We confirmed the previously
observed ‘atypical’ microglial activation during neurode-
generation in the SN in the 6-OHDA model (Depino et al.,
2003). This type of activation included transcription, but
not translation, of major pro-inflammatory cytokines such
as IL-1b and a stage 3, mostly ED-1-negative microglial
phenotype. These observations correlate well with the
biology of the chronic neurodegenerative model used:
neuronal cell death in the SNpc is supposed to be apoptotic
(He et al., 2000), which by definition does not cause
inflammation. Moreover, activated macrophages in the
periphery do not express pro-inflammatory cytokines
during phagocytosis of an apoptotic cell (Fadok et al.,
1998). In addition, microglial activation without pro-
inflammatory cytokine production has also been observed
in a model of prion disease (Perry et al., 2002). Many
treatments such as adherence of monocytes to a plastic
surface can induce pro-inflammatory cytokine transcription
uncoupled to translation in a variety of cells but the
presence of an external pro-inflammatory agent such as
LPS always elicits transcription ‘and’ translation of pro-
inflammatory cytokines (Dinarello, 1991). We hypothesized
that, in these microglial cells primed by the neurodegenera-
tion caused by 6-OHDA where pro-inflammatory mRNAs
are increased, but are not translated, a sub-toxic dose of
1892 Brain (2008),131,1880^1894 M.C. P.Godoy et al.LPS could activate the translation of these already
increased pro-inflammatory cytokine mRNAs. In turn,
these increased, translated pro-inflammatory cytokines
could shift the environment to a pro-inflammatory milieu,
causing a toxic effect directly or by for example, the
generation of NO and free radicals. All our data support
this hypothesis. Results obtained by ELISA showed increased
levels of IL-1 only in the 6-OHDA/LPS animals and the
inhibition of this cytokine by the inoculation of AdIL-1ra
or DXM could reverse the exacerbating effect. Sub-toxic
levels of IL-1 were able to exacerbate 6-OHDA toxicity per se
or by inducing other molecules such as NO. Interestingly,
IL-1 inhibition had no effect on microglial activation,
indicating that IL-1 production was a downstream event
after microglial activation. In addition, NO inhibition did not
significantly alter IL-1 production, suggesting that IL-1
induction is an upstream event from NO production.
These results support the emerging view that a second,
pro-inflammatory stimulus on a region already under
degeneration, can trigger increased IL-1 production and
shift the equilibrium towards increased neurodegeneration.
Indeed, Cunningham et al. (2005) have recently found that
IL-1 could exacerbate disease symptoms in a prion disease
model. Koprich et al. (2008) demonstrate that prior
exposure to LPS renders animals more susceptible to a
sub-toxic dose of 6-OHDA. Importantly, in their ‘mirror
image’ approach, IL-1 blockage also leads to an ameliora-
tion of the toxic effects observed, reinforcing the notion
that IL-1 is a key component of the inflammatory response
that leads to Parkinson’s disease onset or exacerbation.
In the present study, DXM treatment was also able to
prevent inflammation-induced exacerbation of neuronal
loss. From previous studies, other inflammatory mediators
such as COX-2, free radicals, and nitric oxide have been
proposed as targets of anti-Parkinson’s disease therapies.
(Hirsch and Hunot, 2000; Vila et al., 2001; Sanchez-
Pernaute et al., 2004). Indeed, the use of minocycline, an
antibiotic with anti-inflammatory and anti-apoptotic prop-
erties is being tested in a Phase III clinical trial for PD
(NINDS-NET-PD-Investigators, 2006). In addition, an
epidemiological study has associated the chronic use of
ibuprofen with a 0.62–0.73 reduced risk of Parkinson’s
disease (Chen et al., 2005).
Our work identifies for the first time a clinically relevant
animal model where inflammation is unequivocally detri-
mental to the SN. The major clinical impact we suggest is
that central or systemic inflammation should be considered
a risk factor for Parkinson’s disease and should be effici-
ently handled or prevented in Parkinson’s disease patients
to reduce exacerbated disease progression. The identifica-
tion of other molecular inflammatory targets and the
extension of the present observations using additional
systemic inflammatory models should help in defining the
best therapeutic option for the prevention or inhibition of
the exacerbating effects of inflammation in Parkinson’s
disease patients.
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